首页> 外文期刊>Ukrainian Biochemical Journal >Evaluation of antiproliferative activity of pyrazolothiazolopyrimidine derivatives
【24h】

Evaluation of antiproliferative activity of pyrazolothiazolopyrimidine derivatives

机译:吡唑并噻唑并嘧啶衍生物的抗增殖活性评估

获取原文
           

摘要

The research aim was to test cytotoxic effects in vitro of seven novel pyrazolothiazolopyrimidine derivatives in targeting several lines of tumor and pseudo-normal mammalian cells. We demonstrated that cytotoxic effects of these derivatives depended on the tissue origin of targeted cells. Leukemia cells were found to be the most sensitive to the action of compounds 2 and 7 . Compound 2 demonstrated approximately two times higher toxicity towards the multidrug-resistant sub-line of HL-60/ADR cells compared to the Doxorubicin effect. Antiproliferative action of compounds 2 and 7 dropped in the order: leukemia melanoma hepatocarcinoma glioblastoma colon carcinoma breast and ovarian carcinoma cells. These compounds were less toxic than Doxorubicin towards the non-tumor cells. The novel pyrazolothiazolopyrimidine, compound 2 , demonstrated high toxicity towards human leukemia and, of special importance, towards multidrug-resistant leukemia cells, and low toxicity towards pseudo-normal cells.
机译:研究目的是在体外测试七种新型吡唑并噻唑并嘧啶衍生物对几种肿瘤细胞和伪正常哺乳动物细胞的细胞毒性作用。我们证明了这些衍生物的细胞毒性作用取决于靶细胞的组织起源。发现白血病细胞对化合物2和7的作用最敏感。与阿霉素作用相比,化合物2对HL-60 / ADR细胞的多药耐药亚系的毒性大约高出两倍。化合物2和7的抗增殖作用依次下降:白血病>黑色素瘤>肝癌>胶质母细胞瘤>结肠癌>乳腺癌和卵巢癌细胞。这些化合物对非肿瘤细胞的毒性小于阿霉素。新型吡唑并噻唑并嘧啶,化合物2,显示出对人白血病的高毒性,特别是对耐多药性白血病细胞的毒性,对伪正常细胞的毒性低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号